TRAIL R1

TRAIL R1

TRAIL R1 詳細

Molecule Name
Tumor necrosis factor receptor superfamily member 10A
分子の別称
TNFRSF10A,TRAIL-R1,CD261,APO2,DR4
Drug Development Progress
治験薬の数3
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,TRAILR-1,CD261,TNF-related apoptosis-inducing ligand receptor 1,Tumor Necrosis Factor Receptor Superfamily Member 10a Variant 2
バックグランド
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

TRAIL R1 製品リスト

Species
  • Human(2)
Tag
  • Fc Tag(1)
  • His Tag(1)
Host
  • HEK293(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
TRAIL R1
Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag
Human
HEK293
SDS-PAGE
ELISABLI

$285.00

100ug
TRAIL R1
Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISABLI

$285.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Dulanermin (Shanghai GeBaiDe)Phase 3 ClinicalShanghai Gebaide Biotechnology Co Ltd
Carcinoma, Non-Small-Cell Lung
詳細
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)Phase 3 ClinicalShenzhen Sinobioway Xinpeng Biomedicine Co Ltd
Neoplasms
詳細
HLX56HLX56; HLX-56Phase 1 Clinical
Solid tumours
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
AponerminApprovedBeijing Shadong Biotech Co Ltd沙艾特, ShaiteMainland ChinaMultiple MyelomaWuhan Hiteck Biological Pharma Co Ltd2023-11-02
Multiple Myeloma
詳細
Customer Reviews